Anti-Human CTLA-4 (Ipilimumab) – Fc Muted™ Biotin

Pricing & Details

Product No.LT1606
Clone
MDX-010
Protein
CTLA-4
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3
Isotype
Human IgG1κ
Applications
ELISA
,
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT1606-100 μg
100 µg
$325.00
Made to Order
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Human
Expression Host
HEK-293
FC Effector Activity
Muted
Immunogen
Human CTLA-4
Product Concentration
0.5 mg/ml
Formulation
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA
Additional Reported Applications For Relevant Conjugates ?
B
CyTOF®
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.
Antigen Distribution
CTLA4 is constitutively expressed in regulatory T cells.
Background
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Inhibitory Molecules

References & Citations

1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33.
2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741.
3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62.
Elisa Sandwich Protocol
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.